Asset Details
Do you wish to reserve the book?
Subacromial injection failure in shoulder impingement: is somatic amplification the missing link?
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Subacromial injection failure in shoulder impingement: is somatic amplification the missing link?
Do you wish to request the book?
Subacromial injection failure in shoulder impingement: is somatic amplification the missing link?
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Subacromial injection failure in shoulder impingement: is somatic amplification the missing link?
2025
Overview
Objectives: To investigate whether somatosensory amplification - a heightened sensitivity to normal bodily sensations - affects the clinical response to corticosteroid injection in shoulder impingement syndrome (SIS) patients who did not respond to conservative treatment. Methods: This prospective observational study included 70 patients with SIS and persistent pain despite at least four weeks of physical therapy and non-steroidal anti-inflammatory drugs (NSAIDs). All patients received a standardized corticosteroid injection into the subacromial space under ultrasound guidance. Pain intensity was measured using the Visual Analog Scale (VAS) at rest (VAS-rest) and during movement (VAS-movement), while shoulder-related disability was assessed with the Shoulder Pain and Disability Index (SPADI) at baseline and one month after the injection. Somatosensory amplification - referring to increased sensitivity to normal bodily sensations—was evaluated using the Somatosensory Amplification Scale (SSAS), a brief self-report questionnaire administered at the one-month follow-up by a psychiatrist blinded to clinical outcomes. Treatment response was defined as a ≥30% reduction in VAS-movement, based on the minimal clinically important difference (MCID). Patients were categorized as responders or non-responders accordingly. Results: Thirty (42.9%) patients were classified as responders and 40 (57.1%) as non-responders. At 1-month, non-responders had significantly higher SSAS scores than responders (30.7 [27.4-32.6] vs. 21.5 [19.4-23.4], P<0.001). Compared to non-responders, the responder group demonstrated more significant improvements in VAS-rest, VAS-movement, and SPADI scores (P<0.001 for all). Spearman correlation analysis revealed strong positive correlations between SAS and VAS-rest (r=0.732), VAS-movement (r=0.748), and SPADI (r=0.734); P<0.001 for all. Conclusions: Higher levels of somatosensory amplification were linked to a lower likelihood of benefiting from subacromial injection in SIS. These findings support the importance of including psychosomatic assessment in routine care to improve treatment outcomes and guide more personalized management.
Publisher
The Association of Health Research & Strategy
Subject
